Skip to main content
IMS Events Main banner
Back

    Suzanne Lentzsch, MD, PhD (she/her/hers)

    Professor of Medicine
    Columbia University, New York, United States

    Dr. Lentzsch is a Professor of Medicine, Director of the Multiple Myeloma & Amyloidosis Service at the CUMC. She received her degrees from the Humboldt University/Charité Berlin, Germany, completed her residency/fellowship at Humboldt University, and a research fellowship under the mentorship of Dr. Kenneth Anderson at the Dana-Farber Cancer Institute, Boston. In August 2004, joined the University of Pittsburgh as Clinical Director of The Multiple Myeloma Program. Her translational research focuses on identifying novel targets for the treatment of Multiple Myeloma bone disease and AL amyloidosis. Her innovative research resulted in a series of translational clinical trials, such as Bendamustine as a new treatment for relapsed AL amyloidosis. In an FDA-funded, first-in-human phase 1 clinical trial, she studied whether the monoclonal antibody 11-1F4 (Cael-101), targeting amyloid fibrils, can break down amyloid and subsequently improve organ function in patients. Her studies led to the funding of Caelum Biosciences, and Cael-101 is currently being tested in a phase 3 trial.
    Dr. Lentzsch co-chairs the NCI Myeloma Steering Committee and several data monitoring committees. She serves on the Scientific Committee on Plasma Cell Neoplasia for ASH and ASCO and as Associate Editor for JCO. She co-chairs the Career Development Committee of the International Myeloma Society and is a regular reviewer for the NIH and the Leukemia and Lymphoma Society (SCOR and TRP grants). Her research is funded by multiple RO1s, and awards from the Pennsylvania Department of Health, German Cancer Foundation, Leukemia, and Lymphoma Society, Multiple Myeloma Research Foundation, Cancer Research Institute, Emerson Collect Fund, and the International Myeloma Society. As a frequent lecturer, she presents at annual meetings of the American Society of Hematology and the American Society of Clinical Oncology, of which she is also a member. Dr. Lentzsch has published over 140 original articles, editorials, and chapters in high-impact journals.

    Disclosure information not submitted.

    Presentation(s):